Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BIOVIE INC. (BIVI)

BioVie reports Phase 2 SUNRISE-PD topline results for bezisterim in early Parkinson's

Mixed Impact 3 of 5 product/contract Written later

BioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in 57 patients with early-stage Parkinson's disease, with statistically significant improvements versus placebo on several measures. The results are exploratory, the study was small, and the company disclosed no revenue, earnings, or financing figures, so the filing gives shareholders clinical data rather than financial results.

Key points

  • Trial of 57 patients randomized 1:1 to 20 mg bezisterim or placebo twice daily for 12 weeks
  • Composite EPNIC-15 endpoint: bezisterim -0.04 vs. placebo +0.18 (p=0.0006), per the company
  • Reported adverse event incidence of 39.3% with bezisterim vs. 51.7% with placebo; no severe or serious adverse events
  • Conference call set for 4:15 p.m. EDT on August 12, 2026

The filing

CompanyBIOVIE INC. (BIVI)
Form8-K, current report
Filed with the SECAug 6, 2026, 7:35 AM ET
Accession number0001520138-26-000312

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.